Pharmaceutical industry-led access programmes are increasing in number and scope worldwide. We present a new standardised framework for evaluation of these programmes that includes three components: a taxonomy of 11 access programme strategies; a series of logic models, one for each strategy and a set of measurement indicators. The logic models describe pathways of potential programme impact. Concepts relevant across a broad range of strategies were prioritised for inclusion in logic models to ensure consistency and to facilitate synthesis and learning across programmes. Each concept has at least one corresponding measurement indicator with metadata that includes the definition, details on how it should be measured and recommended data sources. The framework establishes a shared language for the collection and reporting of meaningful industry-led access programme information. Broad adoption by programme developers and implementing partners in the for-profit sector and beyond could facilitate shared learning on effective strategies and best practices.
- health systems evaluation
- public health
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
Statistics from Altmetric.com
Handling editor Seye Abimbola
Contributors All authors were involved in creating the measurement framework. PCR wrote the first draft of the manuscript. All the authors were involved in substantially reviewing and revising the manuscript. All the authors have read and approved the final draft of the manuscript.
Funding This work was funded through a grant from Access Accelerated, an initiative of more than 20 global biopharmaceutical companies in partnership with the World Bank and Union of International Cancer Control that seeks to reduce barriers to prevention, treatment and care for non-communicable diseases in low-income and middle-income countries. The funder had no role in final decisions on the design of the framework nor in the writing of the manuscript or the decision to publish. The Master Services Agreement governing this work is available at: http://sites.bu.edu/evaluatingaccess-accessaccelerated/agreements/.
Competing interests All authors report grants from Access Accelerated, during the conduct of the submitted work. PCR reports grants from Sandoz International GmBH and Gilead Sciences, outside the submitted work. ROL reports non-financial support from Novartis International AG and grants from Sandoz International GmBH and Gilead Sciences, outside the submitted work. NS reports a grant from MSD for Mothers, outside the submitted work. PA report a grant from Sandoz International GmBH, outside the submitted work. EHL reports personal fees from Vertex Pharmaceuticals, outside the submitted work. VJW reports grants from Sandoz International GmBH and Gilead Sciences, outside the submitted work.
Patient consent for publication Not required.
Provenance and peer review Not commissioned; externally peer reviewed.
Data availability statement All data are available at www.accessobservatory.org.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.